TrialDiabetes, obesity & metabolism2026

SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications.

Jan W Eriksson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.